Article
Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction.
The oncologist - 10 Apr 2026
Funk Maximilian Alexander, Heinemann Volker, Bücklein Veit, Alig Stefan Karl, Heinrich Kathrin, Weiss Lena, Krenmayr Victoria, Blanchet Benoit, Kunz Wolfgang Gerhard, Theurich Sebastian, von Bergwelt-Baildon Michael, Holch Julian Walter
Abstract excerpt
The activating BRAF mutation V600E occurs in 8%-12% of metastatic colorectal cancers (mCRC) and is associated with peritoneal carcinomatosis (PC) and poor prognosis. Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.